Aims: Ventricular arrhythmia (VA) bursts following recanalisation in acute ST-elevation myocardial infarction (STEMI) are related to larger infarct size (IS). Inadequate microvascular reperfusion, as determined by microvascular obstruction (MVO) using cardiac magnetic resonance imaging (CMR), is also known to be associated with larger IS. This study aimed to test the hypothesis that VA bursts identify larger infarct size in spite of optimal microvascular reperfusion. Methods: All 65 STEMI patients from the Maastricht ST elevation (MAST) study with brisk epicardial flow (TIMI 3), complete ST recovery post-percutaneous coronary intervention and early CMR were included. Using 24-hour Holter registrations from the time of admission, VA bursts were identified against subject-specific Holter background VA rates using a statistical outlier method. MVO and final IS were determined using delayed enhancement CMR. Results: MVO was present in 37/65 (57%) of patients. IS was significantly smaller in the group without MVO (median 9.4% vs. 20.5%; p < 0.001). IS in the group with MVO did not differ depending on VA burst (n = 28/37; median 20.8% vs. 19.7%; p = 0.64). However, in the group without MVO, VA burst was associated with significantly larger IS (n = 17/28; median 10.5% vs. 4.1%; p = 0.037). In multivariable analyses, VA burst as well as anterior infarct location remained independent predictors of larger infarct size. Conclusion: In the presence of suboptimal reperfusion with MVO by CMR, VA burst does not further define MI size. However, with optimal TIMI 3 reperfusion and optimal microvascular perfusion (i.e. no MVO), VA burst is associated with larger IS, indicating that VA burst is a marker of additional cell death.
Introduction
Since the advent of recanalisation techniques in acute ST-elevation myocardial infarction (STEMI), ventricular arrhythmias (VAs) upon reperfusion are a frequently recognised phenomenon. Such VAs include ventricular premature beats with long coupling intervals and accelerated idioventricular rhythms. They are hemodynamically well tolerated and originate within the reperfusion zone. 1 In the thrombolytic era, reperfusion VAs were considered to be a favourable non-invasive marker of reperfusion. However, with direct percutaneous coronary intervention (PCI) for STEMI establishing TIMI 3 flow in >90% of patients, reperfusion VAs have been shown to be associated with larger infarct size (IS). 2 A statistical objectification of these reperfusion VAs, in which they were quantified against a subject-specific background VA rate as a new 'burst' of VA following angiographic recanalisation of the infarct artery, has confirmed these findings. [3] [4] [5] [6] [7] The involvement of microvascular obstruction (MVO) in the pathogenesis of VA burst is unknown. MVO is a known marker of additional extensive injury and larger IS, worse left ventricle ejection fraction (LVEF), left ventricle (LV) remodelling and a higher incidence of cardiovascular complications. [8] [9] [10] [11] MVO can be assessed angiographically, characterized by a lower myocardial blush grade (MBG <3), or by using cardiac magnetic resonance imaging (CMR) for MVO. The latter has been found to be a better marker, but is also more difficult to obtain due to the limited availability of magnetic resonance imaging (MRI) equipment and patient factors such as heart failure or claustrophobia. 12 The purpose of our study was to test the hypothesis that VA burst is an additional independent marker of larger IS in the presence of optimal microvascular perfusion from a prospectively gathered, discrete set of patients in whom independent core laboratory assessments of MVO by CMR were available in conjunction with other key mechanistic surrogates such as epicardial recanalisation (TIMI flow) and continuous digital 12-lead electrocardiogram (ECG) for ST recovery and quantitative ventricular rhythm capture.
Methods

Study population
Consecutive patients included in the Maastricht ST-elevation myocardial infarction (MAST) cohort were studied. These patients presented with a first acute STEMI at Maastricht University Medical Center from August 2006 to March 2008 and gave consent to participate in the MAST study. STEMI was defined according to ECG and enzymatic criteria according to the active consensus document during the study time period. 13 Approval of the study was granted by the Medical Ethical Committee of corresponding hospital (MAST p06.0032), and written informed consent was obtained from all patients. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.
Inclusion criteria for the MAST cohort were: (1) symptoms consistent with an acute STEMI lasting for more than 30 minutes but less than 6 hours; (2) ST-elevation of more than 1 mm in anatomically adjacent leads in the initial ECG; (3) primary PCI; and (4) availability of CMR images. Exclusion criteria included: (1) age below 18 years; (2) cardiogenic shock; (3) pregnancy; (4) inability to obtain informed consent; and (5) contraindications for CMR.
Additional exclusion criteria for the purpose of this study were: (1) absence of or poor-quality ECG Holter recording; (2) and/or CMR imaging; (3) previous myocardial infarction (MI); (4) absence of successful epicardial flow restoration defined as TIMI flow ⩽2; (5) and/or stable ST recovery within 240 min; and (6) late ST re-elevation.
Angiographic TIMI flow assessment
TIMI flowe grading is a well validated classification system going from 0-3. It is used to semiquantitatively assess coronary artery perfusion beyond point of occlusion on coronary angiography. TIMI flow grade assessment was performed by the angiographic core laboratory (Maastricht University Medical Center, Maastricht, The Netherlands) post-procedurally and blinded to all patient and other core laboratory data. TIMI flow was graded according to the TIMI trial classification. 14 
ECG data acquisition
Continuous, high-fidelity, digital, 12-lead ECG Holter recording (NEMON 180+, Northeast Monitoring, Inc., Maynard, MA, USA) was started before PCI and continued for an average of 24 hours. This system provided the source data for both continuous ST-segment recovery and VA burst analyses. Quantitative ST-segment recovery analysis was performed on 60-second median beat 12-lead ECGs. Quantitative VA analysis was performed on three-lead beat-to-beat Holter device. ST and VA analyses were performed by independent experts blinded to all other patient and core laboratory data through the collaborative eECG core laboratory program (Duke Clinical Research Institute/Maastricht University Medical Center eECG Core, Durham, NC, USA and Maastricht, The Netherlands) using NEMON Holter for Windows software (NorthEast Monitoring, Inc., Maynard, MA, USA).
Continuous ST recovery analysis
Methods and criteria for continuous 12-lead ST-segment recovery analysis and reperfusion of the culprit lesion have been described in detail previously. 4 In short, peak ST-segment deviation is determined based on the lead with the greatest deviation taken from the most abnormal ECG recorded during monitoring. Stable and complete ST-segment recovery is defined as ⩾50% recovery from previous peak ST-segment levels in the most deviated lead within 240 minutes, lasting >4 hours without further ST-segment evolution (>100 µV). Late ST (re-)elevation defining epicardial vessel re-occlusion (>150 µV re-elevation in the most abnormal lead evolving in <60 minutes) or microvascular insufficiency (>50% peak ST levels persisting for >6 hours in the most abnormal lead) were used to exclude patients from the 'optimal reperfusion biosignature' group included in the current analysis.
Quantitative rhythm analysis
For beat-to-beat quantitative rhythm analysis on all digital three-lead Holter recordings, Holter 5 software (Northeast Monitoring, Inc., Maynard, MA, USA) was used. 5 All automatically assigned waveform labels were manually verified for each cardiac cycle from each subject in order to ensure accurate VA capture according to predefined criteria for ECG interpretation of VAs. 3, 5 Fusion beats (normally conducted ventricular activation fused with ventricular premature complex [VPC] morphology) were also considered to be VPCs. Ventricular fibrillation was excluded from the analysis; every ventricular complex was counted independent of the length of the arrhythmia. To generate quantitative VA rates over a 24-hour period, total VPC counts, for which no distinction between the types of VPC was made, were bundled into 5-minute blocks for temporal correlation with stable ST-segment recovery and angiographic observations ( Figure 1 ).
Defining VA burst
Quantitative VA rates over the course of Holter recordings were incorporated into a statistical outlier detection method in order to automatically separate outliers of VA rates ('VA bursts') from subject-specific background VA counts. Reperfusion VA bursts were defined as VA bursts if they were concomitant with or subsequent to angiographic documentation of re-established TIMI 3 flow in the infarctrelated artery. Study subjects were dichotomously classified into the 'reperfusion VA burst' group or the 'no burst' group. More detailed description of the characterization of reperfusion VA bursts has been published Majidi et al. 5 Figure 1 . Example of a patient with and a patient without ventricular arrhythmia burst. Concomitantly acquired coronary angiography assessments of pre-and post-primary PCI TIMI flow grades in two study subjects (1A and 2A) with a total occlusion in the proximal LAD artery; continuous digital 12-lead electrocardiography monitoring for ST-segment recovery analysis with both subjects having ⩾50% stable ST-segment recovery (1B and 2B); and complete beat-to-beat Holter monitoring for quantitative rhythm analysis identifying (1C) or not identifying (2C) patient-specific ventricular arrhythmia 'bursts' by using independent statistical outlier detection methodology.
CMR protocol
CMR was performed at 5 ± 2 days and 111 ± 11 days after admission. Images were acquired on a 1.5-Tesla MRI system (Intera, Philips Medical Systems, Best, The Netherlands) with a dedicated five-element phased array surface coil. For functional analysis, ECG-gated cine images were obtained in the LV short-axis plane covering the entire LV using a segmented, balanced, steady-state, free precession sequence (slice thickness 6 mm, slice gap 4 mm, average repetition time 
DE-CMR image analysis
Two observers who were blinded to clinical data independently analysed the DE-CMR images using commercially available software (CAAS MRV 3.0, Pie Medical Imaging, Maastricht, The Netherlands). The inter-observer agreement was excellent (κ = 0.9). Discrepancies were resolved by consensus. Endocardial and epicardial borders were manually traced, excluding the papillary muscles, in the end-diastolic and end-systolic short-axis phases in order to determine left ventricular end-diastolic volume, endsystolic volume, stroke volume, ejection fraction and enddiastolic mass. These parameters were indexed for body surface area.
Likewise, endocardial and epicardial contours were manually traced on the DE images, which were viewed as separate sets. IS was quantified on the DE images using an SI threshold of >5 SD above a remote non-infarcted reference region, including areas of MVO (central hypoenhancement within a hyperenhanced area) and expressed as a percentage of LV mass. MVO was quantified by manually tracing the central hypoenhanced area and expressed as a percentage of LV mass (Figure 2 ).
Statistical analysis
Univariable comparisons for baseline characteristics and outcomes in the burst and no burst groups were made using the Student t-test for normally distributed continuous variables, the Wilcoxon rank sum test for non-normally distributed continuous variables and Fisher's exact test for categorical variables. Multivariable linear regression analysis was performed in order to assess whether VA burst remained an independent predictor of IS when corrected for confounders in the population without MVO. Due to the small population size, we were limited to including only one covariate, which was selected by performing univariable regression analyses for known predictors for IS, study origin and treatment assignment. Significant results were included in the multivariable model and the final model was generated by a backward stepwise elimination. The regression model was checked for assumptions, outliers and multicollinearity. Discrepancies were recorded.
A p-value of < 0.05 was considered statistically significant, and all tests were two-sided. Data were analysed using IBM SPSS statistics software version 19 (IBM, Armonk, NY, USA).
Results
Patient characteristics
The study population consisted of 65 patients from a total of 102 included in the MAST study. Exclusion occurred because of inadequate Holter recordings in seven patients, TIMI 3 flow before PCI in 13 patients, no TIMI 3 flow after PCI in 10 patients, one patient withdrew consent before CMR recording, three had poor study quality, three did not obtain stable ST resolution and one experienced late ST reelevation ( Figure 3) . MVO was present in 37 (57%) patients, of whom 28 (76%) experienced a VA burst. VA burst was present in 17 of 28 (61%) patients without MVO. According to the nature of the reperfusion arrhythmias (ventricular premature beats (VPBs) and accelerated idioventricular rhythms (AIVRs)), the arrhythmia bursts were well tolerated and none of the patients experienced symptomatic VAs. Patient characteristics according to MVO status and burst are shown in Table 1 . Most descriptors were comparable across VA burst groups and representative of a typical STEMI population, except for an overall high incidence of current smoking or history of smoking (89-100%) and a relatively low incidence of anterior MI (11-32%).
For the whole population, the median duration of ischaemia (time in minutes from onset of symptoms to first balloon inflation) was 201 minutes, the incidence of anterior MI was 21.5% and the median days to first and second CMR were 5 and 106, respectively. For the subgroups of MVO versus no MVO, the median duration of ischaemia was 201 versus 210 minutes, and the incidence of anterior MI was 27% versus 14.3%. Finally, for the subgroup without MVO, the median duration of ischaemia was 201 versus 217 minutes for burst versus no burst, respectively, and the incidence of anterior MI was 11.2% versus 18.2%. VA burst occurred less frequently in patients who used β-blockers before STEMI if MVO was absent (p = 0.02). There were no significant differences in characteristics between the presence or absence of MVO.
MVO and IS
IS was larger in patients with MVO found on their first DE-CMR (20.2% vs. 9.5%; p < 0.001) (Figure 4 ), and this difference remained, as observed at the second DE-CMR (15.8% vs. 5.8%; p < 0.001). Accordingly, LVEF was significantly lower in the presence of MVO (49.9% vs. 57.3%; p < 0.001). In the presence of MVO, the presence of VA burst was not associated with a further increase in IS or a lower LVEF.
However, in the absence of MVO but with VA burst, IS was twice as large (10.5% vs. 4.1%; p = 0.037) ( Figure 5 ) at the first DE-CMR and three times as large at the second DE-CMR (8.4% vs. 2.5%; p = 0.048). Univariable regression analyses for patients without MVO showed significant correlations between final IS for VA burst, anterior infarct location, use of β-blockade and gender for both early and late DE-CMR (Table 2) . Angina in the 24 hours proceeding MI had a significant correlation for IS on late DE-CMR. In multivariable analyses, the correlation between VA burst and IS remained significant (B = 6.3, p = 0.02 for early DE-CMR and B = 5.3, p = 0.03 for late DE-CMR) when correcting for the most significant predictor of IS in multivariable analyses, anterior location (Table  3 ). Due to the relatively small infarcts in this study population, LVEF was not significantly affected by the all-ornone presence of VA burst.
Discussion
Our findings confirm previous findings of MVO being correlated with larger IS and lower LVEF. Moreover, VA burst sub-stratifies patients with TIMI 3 flow, ST recovery and absence of MVO in relation to final IS. This suggests VA burst to be an early additional marker that is complementary to TIMI flow, ST-segment resolution and MVO in assessing IS. In the presence of MVO and its associated larger IS, VA burst appears to have no additional substratifying value. This is likely due to the already 
Microvascular obstruction
Significantly larger IS and lower LVEF that were observed in the presence of MVO occurred in the event of stable ST recovery within 240 minutes and no re-elevation of the ST segment. This confirms previous findings that, while correlated, MVO is a strong and additional predictor of IS in addition to ST-segment recovery and TIMI flow alone. 10, 15 Microvascular disperfusion can also be assessed by a MBG ⩽2, but recent studies have shown that MBG underestimates the presence of MVO. 12, 16 MVO has been shown to be a dynamic process that continues to develop up to 48 hours after reperfusion. [17] [18] [19] This is because MVO is not only the result of long, intensive ischaemia and angioplastyinduced distal coronary embolisation, but is also brought on by the reperfusion process, leading to oedema, inflammation and oxidative stress, among others. 20 The effects of reperfusion will become apparent directly after PCI, but will accumulate in the first days after reperfusion. This may also Results presented as mean ± SD, median with quartiles or as n (%). *Significant difference. ACE: angiotensin-converting enzyme; ADP: adenosine diphosphate; AMI: acute myocardial infarction; AP: angina pectoris; AT: angiotensin; BMI: body mass index; CMR: cardiovascular magnetic resonance imaging; MVO: microvascular obstruction; n.a.: not applicable; PCI: percutaneous coronary intervention.
go some way to explaining why MBG, as assessed early during reperfusion, misses cases of MVO that are later found on DE-CMR. In the presence of MVO, the additional presence of VA burst did not significantly influence IS. This observation suggests that the more upstream damage of the microvasculature that causes a larger IS prevents the downstream myocellular tissue from recovering. However, this does not exclude reperfusion arrhythmias from being likely to occur in the area without microvascular occlusion. There was, however, a visible trend showing that bursts occurred more frequently when the area of MVO was smaller.
VA burst
Our results show that VA burst distinguishes patients with larger infarcts from those with smaller infarcts if optimal epicardial perfusion (TIMI 3 flow), optimal microvascular perfusion and stable ST recovery without re-elevation are present. Our results demonstrate that IS is significantly larger in the first days after the event and that the difference becomes more apparent after more than 3 months if VA burst was present. This latter change in difference over time might be attributed to clearing of necrotic myocardium, inflammatory cells, residual oedema and haemorrhage, as well as replacement by scar tissue. Because of the influence of these factors, previous studies have shown that the majority of infarct healing occurs within the first 3-4 months after the event and continues at a slower rate up to 1 year. [21] [22] [23] [24] Recent research has shown that ticagrelor might have a protective effect on MVO. Our study only included clopidogrel as was per protocol at the time of inclusion. It would be interesting to study whether ticagrelor could influence the incidence of VA burst. 25 
Biosignature of 'optimal' reperfusion
Rapid, complete and stable ST-segment resolution without re-elevation is a well-validated electrocardiographic biomarker of high-quality reperfusion. 4, [26] [27] [28] Over 30 years of experimental and clinical research, much evidence has emerged regarding what constitutes 'optimal' reperfusion. This constitutes a series of mechanistic events: epicardial flow, distal embolisation, microvascular flow, reversal of the ischaemic zone and recovery of the still viable but severely damaged myocytes. The combination of these factors results in the creation of an advancing 'signature' of surrogate biomarkers using angiography, ECG, echocardiography, single-photon emission computed tomography and, more recently, CMR. [2] [3] [4] 6, 7 This report is the first to use the more sensitive and specific CMR imaging as a way to define MVO and select only those patients with full microvascular reperfusion. This subset comprises every optimal perfusion stage up to reversal of the ischaemic zone, however leaving the question as to whether the severely damaged myocytes recovered or died by the reperfusion process.
Our results indicate that VA burst is a marker of additional cell death in the presence of optimal epicardial and microvascular reperfusion. This finding is of clinical and experimental importance. VA burst not only identifies larger infarcts at an early stage following the recanalisation attempt, but also enables research aimed at preventing additional myocellular injury. VA burst has the potential to provide an inexpensive diagnostic tool that can guide medical decision making, for example regarding time to discharge. Furthermore, it can also be used as a measure for additional injury of which the pathophysiology is not yet fully clear. Our results suggest a more downstream myocellular mechanism such as reperfusion injury.
Limitations
This is a small but thoroughly studied population that is useful for insight into strategic approaches using a signature of surrogate markers reflective of key mechanistic steps of reperfusion after STEMI, but is in need of much expanded and prospective work in order to confirm these findings and to understand their prognostic implications and relevance to testing new therapies. This small population limited our ability to conduct a more elaborate multivariable analysis and also to draw confirmative conclusions.
Furthermore, we found a significant difference between the occurrence of VA burst and the use of β-blockers before STEMI. This could be a coincidence because many variables were analysed in a small population and only few used β-blockade. Furthermore, the significant relationship was only present in univariate analyses and did not hold in the multivariate analyses. At most, we can hypothesise that the impact of β-blockade before an ischaemic event may have a relevant impact in patients with otherwise optimal reperfusion.
Late CMR was performed significantly earlier in the population without MVO and without VA burst in comparison to the group without MVO but with VA burst. We consider this to be a chance observation that did not influence IS because of the time between the event and CMR recording.
Conclusion
This study confirms previous findings that the presence of MVO on DE-CMR is correlated with larger IS. In addition, this is the first study to show that in the presence of optimal epicardial and microvascular reperfusion (TIMI 3 flow and absence of MVO on DE-CMR), VA bursts identify significantly larger IS in STEMI patients. VA burst has the potential to provide an inexpensive diagnostic tool that can guide medical decision making, for example regarding time to discharge. Furthermore, it can also be used as a measure for additional injury of which the pathophysiology is not yet fully clear. Our results suggest a more downstream myocellular mechanism such as reperfusion injury.
